Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash from Financing Activities (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Cash from Financing Activities for 11 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 13.78% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.5 million through Dec 2025, up 146.85% year-over-year, with the annual reading at $38.5 million for FY2025, 146.85% up from the prior year.
  • Cash from Financing Activities hit $5.8 million in Q4 2025 for Aptevo Therapeutics, down from $18.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $23.9 million in Q1 2021 to a low of -$4.9 million in Q1 2022.
  • Historically, Cash from Financing Activities has averaged $4.4 million across 5 years, with a median of $4.0 million in 2024.
  • Biggest five-year swings in Cash from Financing Activities: crashed 138.22% in 2022 and later skyrocketed 968.8% in 2023.
  • Year by year, Cash from Financing Activities stood at -$3.1 million in 2021, then skyrocketed by 294.99% to $6.0 million in 2022, then plummeted by 49.22% to $3.0 million in 2023, then surged by 120.62% to $6.7 million in 2024, then dropped by 13.78% to $5.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for APVO at $5.8 million in Q4 2025, $18.3 million in Q3 2025, and $14.4 million in Q2 2025.